Bevacizumab and ranibizumab in exudative age-related macular degeneration: Is the effectiveness conditioned by accessibility?

LUNA J.D; REAL, JP; URRETS-ZAVALIA J.A; JUAREZ CP; PALMA SD; GRANERO, G

Seattle

Congreso; ARVO Annual Meeting 2013; 2013

ARVO - Association for Research in Vision and Ophthalmology

Purpose: To evaluate different accessibilities to NV-AMD treatment in clinical practice and estimate their impact on therapeutic effects and visual outcome. Methods: A retrospective analysis of the charts of 78 patients (96 eyes) with previously untreated exudative AMD, who were treated with ranibizumab (RNB) or bevacizumab (BVZ) between January 2009 and December 2011, was conducted. Patients with history of laser photocoagulation treatment, verteporfin photodynamic therapy (PDT) or prior intravitreal therapy were excluded from the analysis The main outcomes measured included time delay and change in mean best-corrected visual acuity (BCVA) between diagnosis and treatment, annual mean number of injections and follow-up examinations and the major clinical outcomes (mean BCVA change and proportion of patient who lost 15 letters) at 1 year of follow-up Results: Both studied groups showed a statistically significant reduction in BCVA (p